PMCB
Income statement / Annual
Last year (2026), PharmaCyte Biotech Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2026, PharmaCyte Biotech Inc's net income was -$19.42 M.
See PharmaCyte Biotech Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2026
|
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
04/30/2026 |
04/30/2025 |
04/30/2024 |
04/30/2023 |
04/30/2022 |
04/30/2021 |
04/30/2020 |
04/30/2019 |
04/30/2018 |
04/30/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$391.30 K
|
$438.42 K
|
$407.43 K
|
$468.54 K
|
$690.94 K
|
$916.25 K
|
$301.22 K
|
$460.05 K
|
$2.00 M
|
$1.18 M
|
| General & Administrative Expenses |
$4.91 M
|
$3.94 M
|
$6.11 M
|
$4.75 M
|
$2.16 M
|
$418.15 K
|
$1.94 M
|
$3.64 M
|
$4.98 M
|
$3.26 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.59 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.91 M
|
$3.94 M
|
$6.11 M
|
$4.75 M
|
$2.16 M
|
$418.15 K
|
$3.53 M
|
$3.64 M
|
$4.98 M
|
$3.26 M
|
| Other Expenses |
$1.55 M
|
$0.00
|
$2.00 M
|
$1.23 M
|
$1.54 M
|
$2.29 M
|
$0.00
|
-$52.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$6.85 M
|
$4.38 M
|
$8.52 M
|
$6.46 M
|
$4.39 M
|
$3.62 M
|
$3.83 M
|
$4.10 M
|
$6.98 M
|
$4.44 M
|
| Cost And Expenses |
$6.85 M
|
$4.38 M
|
$8.52 M
|
$6.46 M
|
$4.39 M
|
$3.62 M
|
$3.83 M
|
$4.10 M
|
$6.98 M
|
$4.44 M
|
| Interest Income |
$733.35 K
|
$1.42 M
|
$3.40 M
|
$1.94 M
|
$157.65 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$509.00
|
$3.05 K
|
$453.00
|
$0.00
|
$0.00
|
$1.54 K
|
| Depreciation & Amortization |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$4.44 M
|
| EBITDA |
-$5.30 M |
-$4.38 M |
-$6.52 M |
-$6.46 M |
-$4.24 M |
-$3.55 M |
-$3.83 M |
-$4.10 M |
-$6.98 M |
-$4.44 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$12.57 M
|
$35.03 M
|
$8.85 M
|
$2.14 M
|
$152.85 K
|
$71.75 K
|
-$493.00
|
$33.40 K
|
$152.59 K
|
-$1.54 K
|
| Income Before Tax |
-$19.42 M
|
$30.66 M
|
$333.76 K
|
-$4.32 M
|
-$4.24 M
|
-$3.55 M
|
-$3.83 M
|
-$4.07 M
|
-$6.83 M
|
-$4.44 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$4.44 K
|
| Net Income |
-$19.42 M
|
$30.66 M
|
$333.76 K
|
-$4.32 M
|
-$4.24 M
|
-$3.55 M
|
-$3.83 M
|
-$4.07 M
|
-$6.83 M
|
-$4.44 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.77 |
3.19 |
-1.8 |
-0.22 |
-0.27 |
-2.45 |
-4.23 |
-5.55 |
-10.57 |
-7.88 |
| EPS Diluted |
-2.77 |
3.19 |
-1.8 |
-0.22 |
-0.27 |
-2.45 |
-4.23 |
-5.55 |
-15 |
-15 |
| Weighted Average Shares Out |
$7.01 M
|
$7.33 M
|
$185.00 K
|
$19.49 M
|
$15.52 M
|
$1.45 M
|
$903.00 K
|
$733.00 K
|
$455.00 K
|
$296.00 K
|
| Weighted Average Shares Out Diluted |
$8.38 M
|
$7.33 M
|
$9.58 M
|
$19.49 M
|
$15.52 M
|
$1.45 M
|
$903.81 K
|
$733.44 K
|
$645.79 K
|
$563.57 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
